RO4905417

Hoffmann-La Roche · Phase 2 active Small molecule

At a glance

Generic name	RO4905417
Sponsor	Hoffmann-La Roche
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention (PHASE2)
A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD). (PHASE1)
A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RO4905417 CI brief — competitive landscape report
RO4905417 updates RSS · CI watch RSS
Hoffmann-La Roche portfolio CI